Research programme: aldosterone synthase inhibitors - ElexoPharm/Merck

Drug Profile

Research programme: aldosterone synthase inhibitors - ElexoPharm/Merck

Alternative Names: CYP11B2 inhibitors - ElexoPharm; Cytochrome P-450 CYP11B2 inhibitors - ElexoPharm

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator ElexoPharm GmbH
  • Developer ElexoPharm GmbH; Merck & Co
  • Class Cardiovascular therapies
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top